Introduction and Objective: The Omnipod 5 App for iPhone allows users to interact with the Omnipod 5 System and discreetly manage their diabetes via personal smartphone. This study evaluated real-world bolusing behaviors in adolescent and young adult Omnipod 5 users with T1D in the US switching to the iPhone app.Methods: A retrospective analysis of CGM and insulin delivery data from Omnipod 5 users aged 13-25y with self-reported T1D who switched to the iPhone app was conducted. Users with sufficient CGM data (≥14 days with ≥1 reading and ≥75% of days with ≥220 readings) during the 30 days of pre- and post- switching were included.Results: A total of 9,465 users met the inclusion criteria. Median boluses/day increased from 4.2 to 4.5 and from 3.9 to 4.5 in those aged 13-17y and 18-25y, respectively (both p<0.001), after switching (Table). In those previously bolusing <3x/day, daily boluses increased by 22% in each age group (both p<0.001). Among these users, time spent in Automated Mode increased by 2.5% and 3.0% and time in range (70-180 mg/dL) increased by 1.7% and 2.9% in those aged 13-17y and 18-25y, respectively (all p<0.001), with the iPhone app.Conclusion: These results support that iPhone app use is associated with improved user engagement and increased bolusing frequency in adolescent and young adult Omnipod 5 users with T1D.
G.P. Forlenza: Advisory Panel; Medtronic. Research Support; Medtronic, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Tandem Diabetes Care, Inc. Advisory Panel; Tandem Diabetes Care, Inc. Research Support; Abbott. Advisory Panel; Sequel Med Tech. K. Stoterau: Employee; Insulet Corporation. A. Chen: None. L.M. Huyett: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. L. Conroy: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. T.T. Ly: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation.
This study was funded by Insulet Corporation.
Source link

Leave a Reply